ClinicalTrials.gg
CompletedNCT02229461KontaktUpdated Jul 15, 2016Results posted

Naproxen Sodium/ASA Platelet Study

A Phase 1 interventional study of Naproxen Sodium (Aleve, BAY117031) and Acetylsalicylic Acid (Aspirin, BAYE4465) in Hematology, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-15.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.

02

Conditions studied

  • Hematology
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers between 18 - 70 years of age with a (BMI) of approximately 18 to 30 kg/m2, and a total body weight > 50 kg (110 lbs)
  • Female subjects of must be using a medically acceptable form of for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, or a double barrier and have a negative pregnancy test at Screening and immediately prior to product administration on Day 1 and Day 6. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy
  • Results of screening and clinical laboratory tests are within normal range or considered not by the Principal Investigator and the Sponsor
  • Be willing and able to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the protocol
  • Provide a personally signed and dated indicating that the subject has been informed of all pertinent aspects of the trial.

Exclusion criteria

Exclusion Criteria:

  • History of or asthma type symptoms with use of aspirin, naproxen sodium and similar pharmacological agents or components of the products
  • Females who are pregnant or lactating
  • Any disorder of the Aspirin Triad Syndrome (i.e., asthma, rhinitis or nasal polyps), or have chronic urticaria
  • Eighteen to twenty years old with a viral infection, with or without fever within one month prior to start of Run-in Period
  • History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, infectious diseases or
  • Any abnormal laboratory value or physical finding that according to the Investigator that may interfere with the interpretation of the study results or be indicative of an underlying disease state
  • Have taken any medications including NSAIDs (except acceptable forms of ) within 7 days prior to the start of the Run-in Period or throughout the study, unless in the opinion of the Investigator and the Sponsor, the medication will not interfere with the study procedures, data integrity, data interpretation or compromise the safety of the subject
  • Have taken antiplatelet or anticoagulant drugs within 30 days prior to start of the Run-in Period or during their participation in the study
  • Have donated blood or blood components within 30 days prior to study entry
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    IR ASA co-administered with naproxen sodium

    Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Experimental
    IR ASA 30 min after naproxen sodium

    Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Experimental
    IR ASA 8 hours after naproxen sodium

    Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Active comparator
    IR ASA only

    Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.

    Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Experimental
    IR ASA 30 min before naproxen sodium

    Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Experimental
    IR ASA 30 min after first dose of naproxen sodium bid

    Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

Interventions

06

What researchers measure

Primary outcomes

  1. Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration

    Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated.

    Time frame: At hour 24 on Day 16 post treatment

Secondary outcomes

  1. Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration

    Inhibition of serum TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.

    Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 (except 24 hours on Day 16)

  2. Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration

    Inhibition of AA-induced platelet aggregation at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. The platelet aggregation change-from-baseline scores range broadly in large part due to inclusion of participants with low baseline platelet aggregation scores.

    Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19

  3. Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration

    Inhibition of plasma TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.

    Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19

07

Results

Posted Jun 10, 2016

Participant flow

The study was conducted at a single site in United States between 16-Feb-2015 (first patient first visit) and 08-May-2015 (last patient last visit).

Participant flow — Overall Study
MilestoneGroup 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid
Started171717171717
Completed171717171717
Not completed000000

Outcome measures

PrimaryInhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration

Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated.

Time frame:
At hour 24 on Day 16 post treatment
Reported as:
Mean · percentage
Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration
percentageGroup 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid
Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration93.09 (91.50 to NA)87.71 (85.51 to NA)92.87 (91.24 to NA)98.72 (98.49 to NA)95.35 (94.14 to NA)95.65 (94.74 to NA)
SecondaryInhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration

Inhibition of serum TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.

Time frame:
At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 (except 24 hours on Day 16)
Reported as:
Mean · percentage
Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration
percentageGroup 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid
Day 7 at 1 hour99.86 (99.82 to NA)99.83 (99.81 to NA)99.69 (99.63 to NA)99.67 (99.60 to NA)99.91 (99.87 to NA)99.84 (99.81 to NA)
Day 7 at 3 hour99.84 (99.79 to NA)99.79 (99.76 to NA)99.54 (99.46 to NA)99.66 (99.58 to NA)99.86 (99.81 to NA)99.80 (99.77 to NA)
Day 7 at 6 hour99.69 (99.58 to NA)99.67 (99.60 to NA)99.44 (99.34 to NA)99.48 (99.36 to NA)99.75 (99.63 to NA)99.70 (99.65 to NA)
Day 7 at 12 hour99.59 (99.46 to NA)99.48 (99.42 to NA)99.12 (98.98 to NA)99.31 (99.17 to NA)99.68 (99.57 to NA)99.63 (99.56 to NA)
Day 7 at 18 hour99.18 (99.01 to NA)99.18 (99.04 to NA)99.76 (99.71 to NA)98.86 (98.68 to NA)99.39 (99.19 to NA)99.70 (99.64 to NA)
Day 7 at 24 hour99.01 (98.76 to NA)99.55 (99.43 to NA)97.78 (96.51 to NA)98.71 (98.46 to NA)99.23 (99.00 to NA)99.80 (99.75 to NA)
Day 16 at 1 hour99.06 (98.79 to NA)98.38 (98.10 to NA)98.32 (98.09 to NA)99.71 (99.64 to NA)99.28 (99.08 to NA)98.81 (98.59 to NA)
Day 16 at 3 hour98.80 (98.49 to NA)97.67 (97.41 to NA)98.02 (97.68 to NA)99.68 (99.60 to NA)99.19 (99.00 to NA)98.53 (98.23 to NA)
Day 16 at 6 hour97.69 (97.21 to NA)96.26 (95.70 to NA)97.40 (97.03 to NA)99.55 (99.45 to NA)98.43 (98.05 to NA)97.51 (97.10 to NA)
Day 16 at 12 hour96.59 (95.67 to NA)92.71 (91.13 to NA)96.31 (95.68 to NA)99.42 (99.29 to NA)97.84 (97.10 to NA)95.38 (94.13 to NA)
Day 16 at 18 hour94.19 (93.04 to NA)92.23 (90.24 to NA)95.68 (94.62 to NA)99.01 (98.85 to NA)96.45 (95.43 to NA)97.73 (97.28 to NA)
Day 17 at 1 hour95.71 (94.31 to NA)94.63 (93.66 to NA)95.56 (94.69 to NA)99.70 (99.64 to NA)97.42 (96.88 to NA)96.95 (96.30 to NA)
Day 17 at 3 hour95.49 (94.38 to NA)92.79 (91.36 to NA)96.43 (95.89 to NA)99.68 (99.60 to NA)96.96 (96.33 to NA)95.92 (95.03 to NA)
Day 17 at 6 hour93.55 (91.86 to NA)90.91 (89.21 to NA)95.64 (94.92 to NA)99.52 (99.41 to NA)95.31 (94.32 to NA)93.91 (92.61 to NA)
Day 17 at 12 hour92.54 (91.08 to NA)91.15 (89.80 to NA)94.13 (93.08 to NA)99.30 (99.13 to NA)94.74 (93.62 to NA)92.60 (90.92 to NA)
Day 17 at 18 hour89.44 (87.48 to NA)87.19 (85.43 to NA)94.23 (93.42 to NA)98.95 (98.76 to NA)93.42 (92.27 to NA)88.14 (85.42 to NA)
Day 17 at 24 hour89.05 (86.86 to NA)83.67 (81.77 to NA)90.39 (88.57 to NA)98.70 (98.48 to NA)91.40 (89.21 to NA)84.27 (80.66 to NA)
Day 19 at 1 hour98.35 (97.86 to NA)97.89 (97.45 to NA)98.89 (98.64 to NA)99.69 (99.62 to NA)98.16 (97.74 to NA)94.06 (92.59 to NA)
Day 19 at 3 hour98.52 (98.02 to NA)97.90 (97.46 to NA)99.05 (98.93 to NA)99.64 (99.55 to NA)98.27 (97.92 to NA)94.44 (92.92 to NA)
Day 19 at 6 hour98.26 (97.78 to NA)97.43 (96.73 to NA)98.98 (98.81 to NA)99.50 (99.39 to NA)97.84 (97.34 to NA)93.25 (91.11 to NA)
Day 19 at 12 hour97.67 (96.95 to NA)96.90 (96.06 to NA)98.77 (98.57 to NA)99.26 (99.09 to NA)97.33 (96.70 to NA)92.00 (89.44 to NA)
Day 19 at 18 hour97.21 (96.40 to NA)96.29 (95.40 to NA)98.52 (98.27 to NA)98.88 (98.67 to NA)96.62 (95.86 to NA)90.94 (88.41 to NA)
Day 19 at 24 hour97.04 (96.13 to NA)96.16 (95.25 to NA)97.98 (97.72 to NA)98.49 (98.19 to NA)96.01 (94.86 to NA)90.67 (88.25 to NA)
SecondaryInhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration

Inhibition of AA-induced platelet aggregation at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. The platelet aggregation change-from-baseline scores range broadly in large part due to inclusion of participants with low baseline platelet aggregation scores.

Time frame:
At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19
Reported as:
Mean · percentage
Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration
percentageGroup 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid
Day 7 at 1 hour58.60 ± 58.89312.78 ± 139.8185.55 ± 306.38987.73 ± 8.77764.14 ± 40.38930.45 ± 182.916
Day 7 at 3 hour-121.76 ± 630.76512.86 ± 144.82310.80 ± 280.40579.16 ± 29.31875.89 ± 24.06718.99 ± 222.208
Day 7 at 6 hour61.74 ± 63.4001.70 ± 168.415-3.29 ± 331.88178.20 ± 33.05173.69 ± 31.85926.91 ± 183.636
Day 7 at 12 hour36.41 ± 162.35028.54 ± 113.063-17.95 ± 275.81180.81 ± 33.24476.02 ± 26.73317.11 ± 249.918
Day 7 at 18 hour62.36 ± 68.38225.27 ± 119.75511.96 ± 280.71878.50 ± 37.67138.58 ± 138.715-151.06 ± 863.434
Day 7 at 24 hour80.60 ± 26.51746.31 ± 91.92441.29 ± 178.08989.12 ± 18.53577.61 ± 29.40144.02 ± 157.466
Day 16 at 1 hour68.96 ± 39.66224.15 ± 114.78229.25 ± 229.74486.12 ± 21.72862.67 ± 45.47445.12 ± 141.196
Day 16 at 3 hour75.25 ± 42.56851.22 ± 74.82533.12 ± 203.70485.92 ± 21.76283.51 ± 21.98637.09 ± 170.694
Day 16 at 6 hour74.45 ± 42.67861.20 ± 63.33362.32 ± 100.84081.36 ± 37.42282.55 ± 17.89381.07 ± 26.570
Day 16 at 12 hour79.88 ± 26.42570.98 ± 51.49911.16 ± 254.04281.38 ± 31.47279.51 ± 21.21853.04 ± 118.315
Day 16 at 18 hour73.86 ± 36.76974.07 ± 40.47335.43 ± 204.05485.19 ± 25.76271.93 ± 52.60271.64 ± 52.123
Day 16 at 24 hour67.47 ± 37.46764.26 ± 51.05015.96 ± 281.84685.25 ± 18.84873.73 ± 32.64851.40 ± 116.489
Day 17 at 1 hour76.23 ± 30.96656.77 ± 63.792-452.48 ± 2088.02783.53 ± 25.47682.13 ± 19.36433.64 ± 197.114
Day 17 at 3 hour78.48 ± 27.96946.16 ± 79.12221.74 ± 255.74283.48 ± 25.46675.15 ± 30.94848.27 ± 117.511
Day 17 at 6 hour76.46 ± 36.01769.16 ± 43.50337.52 ± 204.34183.48 ± 25.51474.61 ± 38.54652.03 ± 131.415
Day 17 at 12 hour83.17 ± 20.39886.40 ± 17.991-24.72 ± 408.99486.00 ± 17.93582.37 ± 27.17267.55 ± 79.461
Day 17 at 18 hour82.30 ± 22.57068.65 ± 45.82431.96 ± 178.29783.71 ± 25.38371.35 ± 31.70941.51 ± 144.334
Day 17 at 24 hour78.66 ± 36.98870.84 ± 46.62253.24 ± 103.24785.43 ± 25.87382.13 ± 29.28687.02 ± 23.703
Day 19 at 1 hour64.06 ± 64.30441.10 ± 103.81621.46 ± 255.47083.97 ± 25.38681.05 ± 19.74343.92 ± 157.676
Day 19 at 3 hour69.18 ± 58.76148.51 ± 73.34123.64 ± 228.47981.62 ± 33.41578.01 ± 26.26514.85 ± 263.930
Day 19 at 6 hour60.96 ± 72.62950.21 ± 77.24251.59 ± 126.75382.98 ± 29.51270.87 ± 35.51558.64 ± 105.239
Day 19 at 12 hour1.08 ± 313.92733.43 ± 110.10536.92 ± 204.36084.45 ± 25.74344.97 ± 112.09913.17 ± 215.066
Day 19 at 18 hour69.69 ± 57.91874.55 ± 46.13015.41 ± 281.25391.12 ± 4.54188.43 ± 10.95384.46 ± 28.685
Day 19 at 24 hour89.86 ± 13.56880.90 ± 28.32929.02 ± 230.05583.67 ± 34.19482.63 ± 20.39371.27 ± 57.042
SecondaryInhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration

Inhibition of plasma TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.

Time frame:
At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19
Reported as:
Mean · percentage
Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration
percentageGroup 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid
Day 7 at 1 hour98.84 (98.35 to NA)98.82 (98.33 to NA)97.59 (96.62 to NA)98.34 (97.61 to NA)99.40 (99.17 to NA)98.67 (98.14 to NA)
Day 7 at 3 hour97.82 (97.00 to NA)98.25 (97.48 to NA)97.72 (97.03 to NA)97.61 (96.55 to NA)98.95 (98.49 to NA)97.68 (96.44 to NA)
Day 7 at 6 hour97.95 (96.59 to NA)98.57 (97.83 to NA)98.37 (97.63 to NA)97.29 (96.46 to NA)99.06 (98.42 to NA)97.93 (97.29 to NA)
Day 7 at 12 hour97.75 (96.69 to NA)97.92 (96.72 to NA)96.66 (95.59 to NA)97.49 (96.71 to NA)98.54 (97.70 to NA)98.36 (97.52 to NA)
Day 7 at 18 hour97.85 (96.65 to NA)96.09 (94.63 to NA)98.79 (98.32 to NA)96.29 (94.83 to NA)97.97 (96.94 to NA)97.87 (96.98 to NA)
Day 7 at 24 hour96.62 (95.38 to NA)98.26 (97.59 to NA)98.89 (98.42 to NA)95.04 (93.35 to NA)98.13 (97.54 to NA)98.44 (97.81 to NA)
Day 16 at 1 hour98.06 (97.15 to NA)95.49 (93.79 to NA)89.55 (87.09 to NA)98.99 (98.59 to NA)96.73 (95.54 to NA)94.95 (92.99 to NA)
Day 16 at 3 hour93.03 (90.35 to NA)89.25 (85.98 to NA)92.62 (90.24 to NA)97.37 (96.45 to NA)96.17 (95.16 to NA)90.62 (87.59 to NA)
Day 16 at 6 hour93.55 (89.83 to NA)88.62 (83.96 to NA)90.40 (88.30 to NA)98.50 (97.89 to NA)95.56 (93.74 to NA)91.27 (87.89 to NA)
Day 16 at 12 hour89.55 (86.80 to NA)85.63 (80.50 to NA)88.76 (85.89 to NA)97.42 (96.77 to NA)92.30 (90.55 to NA)89.45 (84.52 to NA)
Day 16 at 18 hour86.61 (82.69 to NA)84.41 (80.03 to NA)82.14 (75.75 to NA)95.69 (94.57 to NA)93.28 (91.00 to NA)91.03 (87.81 to NA)
Day 16 at 24 hour86.42 (80.81 to NA)72.66 (65.53 to NA)77.71 (72.15 to NA)95.78 (94.35 to NA)88.49 (84.08 to NA)86.87 (81.86 to NA)
Day 17 at 1 hour86.19 (80.48 to NA)79.99 (74.59 to NA)86.14 (83.15 to NA)98.72 (98.30 to NA)93.75 (91.26 to NA)90.00 (84.47 to NA)
Day 17 at 3 hour85.45 (79.85 to NA)90.16 (87.39 to NA)92.60 (90.38 to NA)98.01 (97.13 to NA)88.52 (84.47 to NA)83.94 (78.25 to NA)
Day 17 at 6 hour82.90 (75.87 to NA)84.77 (80.99 to NA)83.08 (77.53 to NA)97.34 (96.57 to NA)92.39 (89.45 to NA)85.82 (79.55 to NA)
Day 17 at 12 hour83.49 (76.38 to NA)81.22 (75.88 to NA)86.50 (82.09 to NA)97.46 (96.40 to NA)92.42 (88.90 to NA)82.13 (76.07 to NA)
Day 17 at 18 hour85.77 (81.67 to NA)78.34 (72.79 to NA)86.53 (82.83 to NA)95.47 (93.79 to NA)85.70 (82.50 to NA)70.90 (62.89 to NA)
Day 17 at 24 hour79.55 (72.74 to NA)79.06 (72.89 to NA)75.67 (70.44 to NA)97.23 (96.19 to NA)92.07 (89.87 to NA)81.34 (76.55 to NA)
Day 19 at 1 hour92.68 (89.50 to NA)89.65 (86.17 to NA)95.32 (93.74 to NA)98.05 (97.37 to NA)94.39 (91.69 to NA)79.36 (73.75 to NA)
Day 19 at 3 hour91.03 (88.18 to NA)92.04 (90.13 to NA)93.68 (91.71 to NA)97.82 (97.16 to NA)94.53 (91.78 to NA)79.82 (74.39 to NA)
Day 19 at 6 hour90.57 (87.64 to NA)91.49 (88.95 to NA)92.35 (90.34 to NA)98.24 (97.66 to NA)93.72 (90.55 to NA)81.14 (77.02 to NA)
Day 19 at 12 hour91.59 (88.31 to NA)89.25 (86.51 to NA)95.18 (93.46 to NA)96.91 (95.87 to NA)92.84 (90.52 to NA)80.66 (75.32 to NA)
Day 19 at 18 hour91.20 (87.58 to NA)93.50 (91.00 to NA)94.85 (92.96 to NA)96.24 (95.27 to NA)92.74 (89.92 to NA)85.67 (81.17 to NA)
Day 19 at 24 hour93.76 (91.18 to NA)90.93 (87.80 to NA)93.66 (91.58 to NA)96.63 (95.39 to NA)96.14 (93.74 to NA)81.67 (74.94 to NA)

Adverse events

Collected over Treatment emergent adverse events were collected after first dose of investigational product on Day 1 until completion of all study procedures throughout the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 0-IR ASA 81 mg qd in Run-in Period—0/102 (0%)0/102 (0%)
Group 1-IR ASA Co-administered With Naproxen Sodium—0/17 (0%)4/17 (23.5%)
Group 2-IR ASA 30 Min After Naproxen Sodium—0/17 (0%)1/17 (5.9%)
Group 3-IR ASA 8 Hours After Naproxen Sodium—0/17 (0%)4/17 (23.5%)
Group 4-IR ASA Only—0/17 (0%)3/17 (17.6%)
Group 5-IR ASA 30 Min Before Naproxen Sodium—0/17 (0%)2/17 (11.8%)
Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid—0/17 (0%)4/17 (23.5%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventGroup 0-IR ASA 81 mg qd in Run-in PeriodGroup 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid
Infrequent bowel movementsGastrointestinal disorders0/1020/170/171/171/170/172/17
Ear painEar and labyrinth disorders0/1021/170/170/170/170/170/17
DiarrhoeaGastrointestinal disorders0/1020/171/170/170/170/170/17
Frequent bowel movementsGastrointestinal disorders0/1020/171/170/170/170/170/17
NauseaGastrointestinal disorders0/1021/170/170/170/170/170/17
Rectal haemorrhageGastrointestinal disorders0/1020/170/170/170/170/171/17
Chest discomfortGeneral disorders0/1020/170/170/170/171/170/17
FatigueGeneral disorders0/1020/170/171/170/170/170/17
Vessel puncture site bruiseGeneral disorders0/1021/170/170/170/170/170/17
ContusionInjury, poisoning and procedural complications0/1020/170/171/170/170/170/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium BidNon-RandomizedTotal
Mean41.3 ± 8.4631.2 ± 7.1937.5 ± 13.4134.2 ± 8.7638.8 ± 12.0938.9 ± 10.6238.2 ± 13.7437.1 ± 11.00
Sex: Female, Male
Sex: Female, Male(Participants)Group 1-IR ASA Co-administered With Naproxen SodiumGroup 2-IR ASA 30 Min After Naproxen SodiumGroup 3-IR ASA 8 Hours After Naproxen SodiumGroup 4-IR ASA OnlyGroup 5-IR ASA 30 Min Before Naproxen SodiumGroup 6-IR ASA 30 Min After First Dose of Naproxen Sodium BidNon-RandomizedTotal
Female746447436
Male1013111313101181
08

Study locations

1 site
  • Austin, Texas 78744, United States
09

References and documents

Publications

  • Gurbel PA, Bliden KP, Zhu J, Troullos E, Centofanti R, Jarvis S, Venkataraman P, Tantry US. Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. J Thromb Thrombolysis. 2018 Jan;45(1):18-26. doi: 10.1007/s11239-017-1593-y. PubMed 29198079 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2014
First posted
Sep 1, 2014
Start
Feb 2015
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jun 10, 2016
Last update
Jul 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02229461
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 1, 2014
Start date
Feb 2015
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 10, 2016
Last update
Jul 15, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion